Trevena (TRVN) Competitors $1.20 -0.02 (-1.64%) As of 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock TRVN vs. PRTG, GRI, SONN, EVOK, VRAX, IMCC, CNSP, TTNP, RDHL, and MAAQShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Portage Biotech (PRTG), GRI Bio (GRI), Sonnet BioTherapeutics (SONN), Evoke Pharma (EVOK), Virax Biolabs Group (VRAX), IM Cannabis (IMCC), CNS Pharmaceuticals (CNSP), Titan Pharmaceuticals (TTNP), RedHill Biopharma (RDHL), and Mana Capital Acquisition (MAAQ). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Portage Biotech GRI Bio Sonnet BioTherapeutics Evoke Pharma Virax Biolabs Group IM Cannabis CNS Pharmaceuticals Titan Pharmaceuticals RedHill Biopharma Mana Capital Acquisition Portage Biotech (NASDAQ:PRTG) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations. Do insiders & institutionals believe in PRTG or TRVN? 13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 42.1% of Portage Biotech shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to PRTG or TRVN? In the previous week, Portage Biotech had 4 more articles in the media than Trevena. MarketBeat recorded 4 mentions for Portage Biotech and 0 mentions for Trevena. Portage Biotech's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score. Company Overall Sentiment Portage Biotech Neutral Trevena Neutral Does the MarketBeat Community favor PRTG or TRVN? Trevena received 603 more outperform votes than Portage Biotech when rated by MarketBeat users. Likewise, 68.67% of users gave Trevena an outperform vote while only 59.09% of users gave Portage Biotech an outperform vote. CompanyUnderperformOutperformPortage BiotechOutperform Votes1359.09% Underperform Votes940.91% TrevenaOutperform Votes61668.67% Underperform Votes28131.33% Do analysts prefer PRTG or TRVN? Trevena has a consensus price target of $5.00, suggesting a potential upside of 316.67%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than Portage Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, PRTG or TRVN? Portage Biotech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Which has preferable earnings and valuation, PRTG or TRVN? Trevena has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPortage BiotechN/AN/A-$75.34M-$41.65-0.13Trevena$443K2.34-$40.29M-$47.04-0.03 Is PRTG or TRVN more profitable? Trevena's return on equity of 0.00% beat Portage Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Portage BiotechN/A -342.34% -196.47% Trevena N/A N/A -119.55% SummaryTrevena beats Portage Biotech on 10 of the 14 factors compared between the two stocks. Remove Ads Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$6.36B$5.28B$7.07BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-0.036.7622.8717.48Price / Sales2.34187.51357.3785.27Price / CashN/A65.6738.1634.64Price / Book-0.115.586.233.79Net Income-$40.29M$141.89M$3.20B$247.10M7 Day Performance-4.00%-11.32%-7.91%-7.31%1 Month Performance-19.46%-14.45%-2.94%-10.19%1 Year Performance-87.97%-18.16%3.18%-7.40% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena0.8713 of 5 stars$1.20-1.6%$5.00+316.7%-87.2%$1.04M$443,000.00-0.0340Upcoming EarningsAnalyst ForecastGap DownPRTGPortage Biotech0.5395 of 5 stars$4.20+1.2%N/A-41.8%$4.41MN/A-0.106Gap UpGRIGRI Bio2.952 of 5 stars$8.06-2.5%$195.50+2,325.6%-98.8%$4.23MN/A-0.701Gap DownSONNSonnet BioTherapeutics2.0469 of 5 stars$1.40+1.4%$20.00+1,328.6%-35.1%$4.23M$1M0.0010News CoverageGap UpTrading HaltedEVOKEvoke Pharma0.7111 of 5 stars$2.81-0.4%N/A-68.8%$4.20M$10.25M-0.264VRAXVirax Biolabs Group2.9728 of 5 stars$1.28+4.9%N/A+18.4%$4.14M$84,872.000.005Analyst RevisionGap UpIMCCIM Cannabis1.0857 of 5 stars$1.79flatN/A-74.0%$4.00M$51.39M-0.53340Earnings ReportCNSPCNS Pharmaceuticals1.307 of 5 stars$3.38-8.9%$25.00+639.6%-99.8%$3.89MN/A-0.055Upcoming EarningsGap UpTTNPTitan Pharmaceuticals0.7542 of 5 stars$4.14-1.2%N/A-43.1%$3.78M$180,000.00-0.7910Analyst ForecastNews CoverageGap UpRDHLRedHill Biopharma0.2815 of 5 stars$2.94-1.8%N/A-99.3%$3.76M$3.71M0.00210Gap DownMAAQMana Capital AcquisitionN/A$0.45+2.3%N/A-66.5%$3.66MN/A0.001High Trading Volume Remove Ads Related Companies and Tools Related Companies PRTG Alternatives GRI Alternatives SONN Alternatives EVOK Alternatives VRAX Alternatives IMCC Alternatives CNSP Alternatives TTNP Alternatives RDHL Alternatives MAAQ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
